India's drug regulator to mandate age warnings on cough syrups for young children

India's drug regulatory authority is set to introduce stricter labeling requirements for cough syrups sold across the country, mandating clear age-based warnings against use in children younger than four years. The proposed measures will include both written alerts and pictorial warnings prominently displayed on packaging, making it immediately apparent to consumers and healthcare providers that these products are unsuitable for infants and very young toddlers.

The regulatory action reflects growing medical and public health concerns about the inappropriate use of cough suppressants and expectorants in the pediatric population. Medical experts have long cautioned that such medications carry risks in very young children, including potential adverse effects and limited evidence of efficacy in this age group.

The initiative aims to reduce accidental misuse and ensure that parents and caregivers are adequately informed before administering cough remedies to infants and toddlers. By implementing standardized visual and textual warnings, the regulator hopes to create a clear communication standard across manufacturers and reduce preventable health incidents.

The proposal is expected to apply to all cough syrup formulations currently marketed in India, requiring manufacturers to reformulate their packaging and labeling within a specified compliance period following official notification.